The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 17, 2020

Filed:

Sep. 12, 2017
Applicant:

Genzyme Corporation, Cambridge, MA (US);

Inventors:

Clark Pan, Sutton, MA (US);

Huawei Qiu, Westborough, MA (US);

Assignee:

GENZYME CORPORATION, Cambridge, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 5/02 (2006.01); C12N 5/16 (2006.01); C12N 1/20 (2006.01); C12N 15/00 (2006.01); C12P 21/06 (2006.01); C12P 21/04 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); A61K 49/00 (2006.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A61K 47/6803 (2017.08); A61K 47/6811 (2017.08); A61K 47/6851 (2017.08); A61K 47/6889 (2017.08); A61K 49/0002 (2013.01); A61K 49/0004 (2013.01); C07K 16/00 (2013.01); C07K 16/2809 (2013.01); C07K 16/2851 (2013.01); C07K 16/2893 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01);
Abstract

Provided are binding polypeptides (e.g., antibodies), and drug conjugates thereof, comprising an Fc domain with an altered glycosylation profile and reduced effector function. In particular embodiment, the Fc domain comprises: an asparagine residue at amino acid position 298, according to EU numbering; and a serine or threonine residue at amino acid position 300, according to EU numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.


Find Patent Forward Citations

Loading…